Biogen Q4 Beat, Leqembi Lift, Nasdaq-100 Exit Now!

Biogen Q4 Beat, Leqembi Lift, Nasdaq‑100 Exit Now!

Biogen Inc. (BIIB) delivered a better-than-expected fourth quarter, powered by growing Leqembi uptake and resilient Tysabri sales. While those wins helped the top and bottom lines, the company still faces headwinds from legacy product declines, guidance that signals modest near-term softness, and a structural hit after its removal from the Nasdaq‑100. The combination of operational progress and index-driven pressure creates a complex risk/reward profile for investors watching BIIB closely.

Q4 performance: the numbers behind the headlines

Top-line and earnings snapshot

Biogen reported adjusted earnings per share of $1.99 for the quarter, comfortably above the roughly $1.63 analysts had expected. Consolidated revenue landed near $2.3 billion, reflecting a mixed portfolio where a few high-growth assets offset softness elsewhere.

Which products moved the needle

Two products were decisive contributors:

• Leqembi: The Alzheimer’s therapy — co-developed with Eisai — posted a sizable year-over-year increase and generated roughly $134 million in the period, a jump of about 54% versus the prior comparable quarter. Leqembi’s momentum underscores its commercial ramp and pricing resilience in a tightly scrutinized therapeutic area.
• Tysabri: The multiple sclerosis franchise weighed in with approximately $397.5 million in sales, outperforming internal expectations and cushioning the portfolio against declines elsewhere.

At the same time, some legacy and rare-disease products underperformed relative to street estimates, illustrating the company’s transitional mix: new launches growing, older franchises facing competition or structural decline.

Guidance and near-term outlook

Management guided to mid-single-digit percentage revenue declines for the full year and a 2026 adjusted EPS range of roughly $15.25–$16.25. That view sits slightly above some analyst forecasts but still signals modest contraction versus peak levels. The key takeaway for investors is that while new-product growth is tangible, it has not yet fully offset declines in established revenue streams.

Implications for valuation

Markets tend to reward predictable growth; Biogen’s mixed message — clear growth in targeted assets but an overall revenue dip — fosters a neutral to cautious consensus. Brokerages largely maintain a Hold stance on BIIB, with average 12‑month price targets clustered near $186, reflecting both the upside from Leqembi and the offset of near-term risks.

Nasdaq‑100 removal: structural pressure on the stock

Biogen’s removal from the Nasdaq‑100, effective December 22, 2025, was driven by market-cap and liquidity thresholds. With market capitalization near $25.5 billion and average daily trading volume below the required floor, BIIB no longer met the index’s eligibility rules.

Why index exclusion matters

• Passive outflows: ETFs and funds that track the Nasdaq‑100 mechanically sold BIIB, reducing demand and compressing trading liquidity.
• Volatility and bid-ask dynamics: Lower index-driven ownership can widen spreads and increase volatility for stocks that lose qualifying status.
• Perception and coverage: Index membership often translates into greater institutional focus; exclusion can reduce the frequency of analyst attention and institutional engagement.

These effects are not fatal but can amplify downside in periods of broader market stress and slow any recovery tied solely to fundamental improvement if trading volume remains muted.

Investor takeaways and positioning

For stock investors, the Biogen case is a study in contrasts. On the fundamental side, Leqembi’s rapid revenue growth and Tysabri’s resilience are clear positives that validate parts of the commercial strategy. On the structural side, the Nasdaq‑100 exit and mixed guidance introduce tangible headwinds to stock performance and liquidity.

Practical considerations for positioning:

• Short to medium term, expect sentiment to be sensitive to monthly Leqembi adoption metrics, Tysabri trends, and any signs of stabilization from older franchises.
• Monitor average daily trading volume; recovery in liquidity would be required before passive investors meaningfully return.
• Valuation is contingent on execution: if new-product growth accelerates and offsets declines, upside is credible; without that, the stock may trade in a range reflecting index-exit pressure.

Conclusion

Biogen’s latest quarter illustrated both progress and transition. Leqembi and Tysabri delivered tangible upside, showing management can extract growth from its newer assets. Yet the firm-wide revenue outlook and the structural consequences of leaving the Nasdaq‑100 temper immediate enthusiasm. For investors, the path forward will hinge on sustained commercial momentum from Leqembi and other launches, together with restoration of trading volume that could ease index-related headwinds.

Careful monitoring of sequential revenue, adoption trends, and liquidity metrics will offer the best real-time signals about whether BIIB’s recent operational gains can translate into a durable re-rating.